Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05276401 · ClinicalTrials.gov registry record · Phase 2
Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
A Phase 2 study, sponsored by Lakewood-Amedex.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05276401 is a Phase 2 study that was terminated before completion, run by Lakewood-Amedex. The registered enrollment target is 3 participants.
The verdict
NCT05276401, a Phase 2 study, was terminated before completion, sponsored by Lakewood-Amedex.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
A PHASE 2a, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATING STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICALLY APPLIED BISPHOSPHOCIN NU-3 GEL TO CLINICALLY NONINFECTED CHRONIC DIABETIC FOOT ULCERS (cDFU)
Interventions
- DRUG 5% Bisphosphocin Topical Gel
- DRUG Placebo Topical Gel
- DRUG 10% Bisphosphocin Topical Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2022-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05276401
The ClinicalTrials.gov registry entry for NCT05276401 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lakewood-Amedex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 5% Bisphosphocin Topical Gel is the first listed.
NCT05276401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05276401 about?
NCT05276401 is a clinical study titled "Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer". A PHASE 2a, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATING STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICALLY APPLIED BISPHOSPHOCIN NU-3 GEL TO CLINICALLY NONINFECTED CHRONIC DIABETIC FOOT ULCERS (cDFU)
What is the current status of trial NCT05276401?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-03-11. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT05276401?
The interventions under investigation include: 5% Bisphosphocin Topical Gel (DRUG), Placebo Topical Gel (DRUG), 10% Bisphosphocin Topical Gel (DRUG).
Who is sponsoring clinical trial NCT05276401?
This trial is sponsored by Lakewood-Amedex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.